DEFINITIVE CONTRACT
Active75F40126C00083
Department of Health and Human Services › Food and Drug Administration › FDA OFFICE OF ACQ GRANT SVCS
$1.5M
obligated · signed 3 weeks ago
BAA FY26C3AP4: A CROSS-SPECIES IMMUNE ORGAN CHIP REFERENCE FRAMEWORK FOR REGULATORY EVALUATION OF VACCINE AND ANTIVIRAL MEDICAL COUNTERMEASURES = EO 14398
Performance timeline
Start
Sep 30, 2026
Current end
Sep 29, 2027
Potential end
Sep 29, 2030
with all options
Loading status
Estimated start: Sep 29, 2029
BOARD OF REGENTS OF NEVADA SYSTEM OF HIGHER EDUCATION
Contract 75F40126C00083
UEI
WLDGTNCFFJZ3
Parent Company
BOARD OF REGENTS OF NEVADA SYSTEM OF HIGHER EDUCATION
Capabilities & Certifications
Headquarters Location
Congressional District: 02
Current Obligation
$1,500,000
Base + Exercised Options
$1,500,000
Total Ceiling Value
$9,900,000
Contract Type
FIRM FIXED PRICE
Multi-Year Contract
NO
NAICS
RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
PSC
GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; BASIC RESEARCH
Place of Performance
Congressional District: 02
Awarding Agency
Top-tier agency
Food and Drug Administration
Sub-tier agency
FDA OFFICE OF ACQ GRANT SVCS
Office
Funding Agency
Top-tier agency
Food and Drug Administration
Sub-tier agency
FDA OFFICE OF ACQ GRANT SVCS
Office
Solicitation procedures, competition exceptions, labor standards and account totals.